Status note CD3 T-cell engaging DARPin against AML; Phase 1 ongoing with potential expansion.
MP0712
Preclinical · ActiveModality: Radio DARPin Therapy (RDT)
Target DLL3
Partnerships Orano Med (subsidiaries of Orano SA): collaboration on Radio DARPin Therapy.
Indications
Small cell lung cancer(Preclinical)
Status note DLL3-targeting RDT; Phase 1 clinical trial being prepared.
MP0726
Preclinical · ActiveModality: Radio DARPin Therapy (RDT)
Target MSLN
Partnerships Orano Med (subsidiaries of Orano SA): collaboration on Radio DARPin Therapy.
Indications
Ovarian cancer(Preclinical)
Status note MSLN-targeting RDT; Phase 0 and Phase 1 clinical trials being prepared.
Per-asset detail extracted from the 20-F filed 2026-03-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.